Drug intelligence / Profile preview

DC9703

Development stage: Preclinical
Lead developer: Obio Pharmaceutical Holdings
Modality: Small Molecules
Administration: Oral

Overview

DC9703 is a botanical drug candidate developed by the Hong Kong-based company Obio Pharmaceutical Holdings Ltd for the treatment of Type 2 Diabetes Mellitus. The drug is derived from *Dendrobium candidum*, a plant species long utilized in traditional Chinese medicine for its purported glucose-lowering properties. DC9703 is designed to regulate blood sugar levels and improve insulin sensitivity through the synergistic action of its complex bioactive components. The developer has secured patents for the drug's composition and therapeutic application in several international jurisdictions, including the United States and South Africa. As a botanical drug, it represents a standardized pharmaceutical formulation of plant extracts rather than a single purified chemical entity.

Other names: Dendrobium candidum extract

Beyond the preview

Go deeper on DC9703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC9703.

Explore the full profile